← Leaderboards
Rosh Chandraratna
Io Therapeutics, Inc.
$2,079,395
Attributed
$2,079,395
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2014–17$1M$750K$500K$250K$0
'14
'15
'16
'17
Funding mix
By agency
NIH$2,079,395 · 2
By mechanism
R44$1,854,395 · 1
R43$225,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Multiple Sclerosis”
- David A. Hafler · Brigham And Women'S Hospital$33,720,341
- Vijay K Kuchroo · Brigham And Women'S Hospital$32,935,587
- Stephen L Hauser · University Of California San Francisco$32,469,388
- Katerina Akassoglou · University Of California San Diego$24,525,425
- Abdolmohamad Rostami · Thomas Jefferson University$23,969,638
- Stephen D Miller · Northwestern University$23,969,272
Research focus
Multiple SclerosisPhase Ii Clinical TrialsFutureMalignant NeoplasmsPeroxisome Proliferator-Activated ReceptorsPharmaceutical PreparationsDoseExperimental Autoimmune EncephalomyelitisImmuneIn VivoNuclear ReceptorsParalysedAgonistBaseBexaroteneClinical ResearchCardiovascular SystemEffective TherapyAnimal ModelGenesCancer PatientInflammatoryCanis FamiliarisPre-Clinical
Grant awards (3)
Development of the RXR agonist IRX4204 to treat Multiple Sclerosis and other Immune related Diseases$1,000,000
R44 · FY2017 · AI · contact PI
Development of the RXR agonist IRX4204 to treat Multiple Sclerosis and other Immune related Diseases$854,395
R44 · FY2016 · AI · contact PI
Development of the RXR agonist IRX4204 to treat Multiple Sclerosis and other Immu$225,000
R43 · FY2014 · AI · contact PI